Literature DB >> 22504935

A clinician-administered severity rating scale for illness anxiety: development, reliability, and validity of the H-YBOCS-M.

Natalia A Skritskaya1, Amanda R Carson-Wong, James R Moeller, Sa Shen, Arthur J Barsky, Brian A Fallon.   

Abstract

BACKGROUND: Clinician-administered measures to assess severity of illness anxiety and response to treatment are few. The authors evaluated a modified version of the hypochondriasis-Y-BOCS (H-YBOCS-M), a 19-item, semistructured, clinician-administered instrument designed to rate severity of illness-related thoughts, behaviors, and avoidance.
METHODS: The scale was administered to 195 treatment-seeking adults with DSM-IV hypochondriasis. Test-retest reliability was assessed in a subsample of 20 patients. Interrater reliability was assessed by 27 interviews independently rated by four raters. Sensitivity to change was evaluated in a subsample of 149 patients. Convergent and discriminant validity was examined by comparing H-YBOCS-M scores to other measures administered. Item clustering was examined with confirmatory and exploratory factor analyses.
RESULTS: The H-YBOCS-M demonstrated good internal consistency, interrater and test-retest reliability, and sensitivity to symptom change with treatment. Construct validity was supported by significant higher correlations with scores on other measures of hypochondriasis than with nonhypochondriacal measures. Improvement over time in response to treatment correlated with improvement both on measures of hypochondriasis and on measures of somatization, depression, anxiety, and functional status. Confirmatory factor analysis did not show adequate fit for a three-factor model. Exploratory factor analysis revealed a five-factor solution with the first two factors consistent with the separation of the H-YBOCS-M items into the subscales of illness-related avoidance and compulsions.
CONCLUSIONS: H-YBOCS-M appears to be valid, reliable, and appropriate as an outcome measure for treatment studies of illness anxiety. Study results highlight "avoidance" as a key feature of illness anxiety-with potentially important nosologic and treatment implications.
© 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22504935      PMCID: PMC4672371          DOI: 10.1002/da.21949

Source DB:  PubMed          Journal:  Depress Anxiety        ISSN: 1091-4269            Impact factor:   6.505


  27 in total

Review 1.  Revising the classification of somatoform disorders: key questions and preliminary recommendations.

Authors:  Kurt Kroenke; Michael Sharpe; Richard Sykes
Journal:  Psychosomatics       Date:  2007 Jul-Aug       Impact factor: 2.386

2.  The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms.

Authors:  Kurt Kroenke; Robert L Spitzer; Janet B W Williams
Journal:  Psychosom Med       Date:  2002 Mar-Apr       Impact factor: 4.312

3.  Overlapping and distinctive features of hypochondriasis and obsessive-compulsive disorder.

Authors:  F Neziroglu; D McKay; J A Yaryura-Tobias
Journal:  J Anxiety Disord       Date:  2000 Nov-Dec

4.  Resource utilization of patients with hypochondriacal health anxiety and somatization.

Authors:  A J Barsky; S L Ettner; J Horsky; D W Bates
Journal:  Med Care       Date:  2001-07       Impact factor: 2.983

Review 5.  Hypochondriasis and its relationship to obsessive-compulsive disorder.

Authors:  B A Fallon; A I Qureshi; G Laje; B Klein
Journal:  Psychiatr Clin North Am       Date:  2000-09

6.  A new, empirically established hypochondriasis diagnosis.

Authors:  Per Fink; Eva Ørnbøl; Tomas Toft; Kaj Christensen Sparle; Lisbeth Frostholm; Frede Olesen
Journal:  Am J Psychiatry       Date:  2004-09       Impact factor: 18.112

7.  Hypochondriasis Y-BOCS: a study of the psychometric properties of a clinician-administered semi-structured interview to assess hypochondriacal thoughts and behaviours.

Authors:  Anja Greeven; Philip Spinhoven; Anton J L M van Balkom
Journal:  Clin Psychol Psychother       Date:  2009 Sep-Oct

Review 8.  Psychotherapies for hypochondriasis.

Authors:  A B Thomson; L A Page
Journal:  Cochrane Database Syst Rev       Date:  2007-10-17

9.  A double-masked, placebo-controlled study of fluoxetine for hypochondriasis.

Authors:  Brian A Fallon; Eva Petkova; Natalia Skritskaya; Arturo Sanchez-Lacay; Franklin Schneier; Donna Vermes; Jianfeng Cheng; Michael R Liebowitz
Journal:  J Clin Psychopharmacol       Date:  2008-12       Impact factor: 3.153

10.  Cognitive behavior therapy for hypochondriasis: a randomized controlled trial.

Authors:  Arthur J Barsky; David K Ahern
Journal:  JAMA       Date:  2004-03-24       Impact factor: 56.272

View more
  3 in total

1.  A Randomized Controlled Trial of Medication and Cognitive-Behavioral Therapy for Hypochondriasis.

Authors:  Brian A Fallon; David K Ahern; Martina Pavlicova; Iordan Slavov; Natalia Skritskya; Arthur J Barsky
Journal:  Am J Psychiatry       Date:  2017-06-29       Impact factor: 18.112

2.  The German version of the H-YBOCS for the assessment of hypochondriacal cognitions and behaviors: development, reliability and validity.

Authors:  Florian Weck; Maria Gropalis; Julia M B Neng; Michael Witthöft
Journal:  Int J Behav Med       Date:  2013-12

Review 3.  Specificity of trait anxiety in anxiety and depression: Meta-analysis of the State-Trait Anxiety Inventory.

Authors:  Kelly A Knowles; Bunmi O Olatunji
Journal:  Clin Psychol Rev       Date:  2020-10-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.